Sr Research Specialist-PPK/PD
Regeneron Pharmaceuticals
Summary
This individual will serve as an independent contributor in the Translational Pharmacokinetics and Pharmacodynamics (TPK/PD) Group.
Job description
- Perform non-compartmental and compartmental PK/PD analyses in support of nonclinical and (potentially) clinical studies using Phoenix WinNonlin and other analysis software
- Prepare and quality-control standardized datasets from CRO and internal bioanalytical data for regulatory submission
- Contribute to PK/TK protocol design/input
- Support CRO studies
- Produce Pharmacometrics deliverables and regulatory tables/figures/listings
- Follow all SOPs to ensure GxP/GLP compliance
Requirements
- Expertise in PK/PD analysis
- Experience with Phoenix WinNonlin or similar analysis software
- Ability to prepare regulatory deliverables
- Experience working within a GxP/GLP regulated environment
Benefits
- Annual bonuses
- Incentive plans
- Equity awards
- Pension or retirement benefits
- 401(k) company match
- Health and wellness programs
- Fitness centers
- Medical, Dental & Vision
- Life and disability insurance
- Paid time off
- Family support benefits
Company overview
Regeneron Pharmaceuticals is a leading American biotechnology company founded in 1988 and headquartered in Tarrytown, New York. The company specializes in inventing, developing, and commercializing life-transforming medicines for people with serious diseases. Regeneron is renowned for its innovative antibody technologies and has developed several groundbreaking therapies, including EYLEA® for retinal diseases, DUPIXENT® for inflammatory conditions, and the COVID-19 antibody cocktail REGEN-COV®. The company operates with a strong focus on research and development across multiple therapeutic areas including ophthalmology, oncology, cardiovascular diseases, and rare genetic disorders. Regeneron's proprietary VelocImmune® technology platform enables the rapid generation of fully human monoclonal antibodies. With over 15,000 employees globally and annual revenues exceeding $14 billion, Regeneron has established itself as a major force in the biotechnology industry, consistently ranking among the top-performing pharmaceutical companies and maintaining a robust pipeline of investigational therapies.